Novo Nordisk’s Wegovy (semaglutide, 2.4mg) Receives the US FDA’s Approval for Weight Management in Adults with Obesity

June 7, 2021 Auto Bot approval, FDA, Novo Nordisk, obesity, regulatory, semaglutide, Wegovy 0

Shots:

  • The approval is based on the results from the P-IIIa STEP clinical trial program evaluating Wegovy (2.4mg injection, qw) in ~4,500 adults with obesity or overweight with at least one weight-related comorbidity
  • Results: the therapy showed 17-18% average weight loss in people without T2D @68wks. and has a safe and well-tolerated profile across the program
  • Wegovy is the first GLP-1 receptor agonist and is expected to launch in the US in Jun’2021. The therapy is currently under regulatory review in the EU and other countries

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Energy Watch

The post Novo Nordisk’s Wegovy (semaglutide, 2.4mg) Receives the US FDA’s Approval for Weight Management in Adults with Obesity first appeared on PharmaShots.